Versant Venture Management, LLC
Versant Venture Management, LLC reported 8 US-listed holdings worth $162.6 million in its 13F for the quarter ended 30 June 2026, filed 12 August 2026. Its largest: Monte Rosa Therapeutics Inc. (47.3%), Century Therapeutics Inc. (18.3%) and Jade Biosciences Inc. (13.6%). Against the quarter before, it opened 0 positions, added to 0, trimmed 1 and sold out of 0.
The 8 largest of its 8 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned -25.7% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Trimmed 1
- Jade Biosciences Inc. JBIO-534,037 shares · -35%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Monte Rosa Therapeutics Inc. GLUE | 3.2M | $77.0 million | 47.34% | no change |
| Century Therapeutics Inc. IPSC | 12.2M | $29.8 million | 18.33% | no change |
| Jade Biosciences Inc. JBIO | 991.8K | $22.0 million | 13.55% | -534.0K |
| Lenz Therapeutics Inc. LENZ | 2.7M | $15.1 million | 9.28% | no change |
| Contineum Therapeutics Inc. CTNM | 542.6K | $8.9 million | 5.47% | no change |
| Crispr Therapeutics AG CRSP | 148.8K | $8.1 million | 4.99% | no change |
| Skye Bioscience Inc. SKYE | 2.0M | $1.4 million | 0.86% | no change |
| Tempest Therapeutics Inc. | 269.8K | $299,447 | 0.18% | no change |